StemBioSys, Inc.

Do you struggle with cells behaving unnaturally or even dying when cultured on ordinary tissue culture plastic (TCP)? Does this make it difficult for you to obtain high-quality cells in large numbers? Dr. Xiao-Dong Chen, a tenured professor at UT Health San Antonio, and his company, StemBioSys, Inc., have the solution - their 𝗖𝗘𝗟𝗟𝘃𝗼™ Matrix technology! Dr. Chen realised that MSCs lose their stem cell properties because critical features of the stem cell niche are absent in TCP, and that to solve this, the body's physiological microenvironment must be replicated. CELLvo™ matrices are the only substrates that aim to recapitulate biochemical, structural and mechanical cues of the native niche by leaving the extracellular matrix intact. Cell-derived matrices create a biologically relevant culture environment for a variety of cell types by providing all the cues cells expect to receive in vivo, in StemBioSys®culture dishes. This means that instead of responding to foreign culture conditions, cells respond to your experimental variables. 𝗧𝗵𝗲 𝗖𝗘𝗟𝗟𝘃𝗼™ 𝗿𝗮𝗻𝗴𝗲: 𝗖𝗘𝗟𝗟𝘃𝗼™ 𝗠𝗮𝘁𝗿𝗶𝘅 - for rapid & reliable cell expansion of MSCs and other adherent cells. 𝗖𝗘𝗟𝗟𝘃𝗼™ 𝗠𝗮𝘁𝗿𝗶𝘅 𝗣𝗹𝘂𝘀  - the next generation of CELLvo™ Matrix technology, initially developed for pluripotent stem cell culture, & subsequently discovered to be the ideal substrate for cardiomyocyte maturation and culture. 𝗖𝗘𝗟𝗟𝘃𝗼™ 𝗫𝗙 𝗠𝗮𝘁𝗿𝗶𝘅 - for rapid & reliable cell expansion of MSCs and other adherent cells, produced xeno-free, allowing easy transition to translational studies. 𝗖𝗘𝗟𝗟𝘃𝗼™ 𝗡𝗲𝘂𝗿𝗼𝗠𝗮𝘁𝗿𝗶𝘅 - provides support to a variety of iPSC-derived and primary neural cell types in mono and co-culture. 𝗖𝗘𝗟𝗟𝘃𝗼™ 𝗖𝗵𝗼𝗻𝗱𝗿𝗼𝗠𝗮𝘁𝗿𝗶𝘅 - for rapid expansion of human articular chondrocytes (HC-a). 𝗖𝗘𝗟𝗟𝘃𝗼™ 𝗖𝗲𝗹𝗹𝘀 are the only commercially available cells isolated and expanded using StemBioSys’ CELLvo™ Matrix technology. By isolating cells on a cell-derived extracellular matrix, natural phenotypes are preserved. All of their cells are early-passage and xeno-free whenever possible. 🛒🔗 https://lnkd.in/ehaGGU4u

In this independent preprint, human iPSC-derived cardiomyocytes cultured on CELLvo™ Matrix Plus formed functional, spontaneously beating monolayers that were successfully analyzed using automated high-throughput contraction imaging. While the study was focused on validating a novel imaging platform rather than comparing matrix coatings, CELLvo Matrix Plus demonstrated compatibility with robust functional cardiomyocyte assays and automated phenotypic analysis. Visit www.stembiosys.com to learn more about CELLvo™ Matrix Plus.

Wishing you a Happy 4th of July Our offices will be closed Friday, July 3rd, 2026.  To celebrate the occasion, we are taking $250 Off all direct orders over $799. Choose from a variety of primary cells or cell-derived matrices.   Happy 4th from our StemBioSys® family to yours!!  Visit our website now to start saving at www.stembiosys.com or Request a quote by emailing us at info@stembiosys.com.

🔬 Not All Endothelial Cells Are Created Equal: HUVECs vs. Cord Blood Endothelial Progenitor Cells (CB-EPCs) When developing vascularized tissue models, angiogenesis assays, or regenerative medicine applications, the choice of endothelial cell source can significantly impact experimental outcomes. Many researchers rely on commercially available HUVECs (Human Umbilical Vein Endothelial Cells), often supplied at Passage 4 or later. While HUVECs are well-established and easy to use, they represent a more mature endothelial phenotype and can exhibit reduced proliferative capacity and angiogenic potential with continued passaging. In contrast, CELLvo™ Cord Blood Endothelial Progenitor Cells (CB-EPCs) from StemBioSys are provided at Passage 3, preserving a more progenitor-like state with several important advantages: ✅ Higher proliferative potential ✅ Enhanced colony-forming ability ✅ Robust vessel network formation ✅ Greater angiogenic activity ✅ Improved consistency for long-term expansion ✅ Demonstrated ability to form perfusable vascular structures Because CB-EPCs originate from circulating endothelial progenitors found in umbilical cord blood, they retain characteristics associated with early vascular development and neovascularization that may be diminished in more mature endothelial cell populations. For researchers building advanced vascular models, organoids, tissue-engineered constructs, or studying angiogenesis, the difference between a mature endothelial cell and an endothelial progenitor cell can be the difference between simply observing cells and creating functional vascular networks. The cell source—and even the passage number—matters. Buy Now at: https://lnkd.in/g2JiEtzn "If your application depends on robust vascular network formation, starting with endothelial progenitor cells rather than mature endothelial cells may provide a more physiologically relevant foundation for your model." #CellCulture #EndothelialCells #HUVEC #Angiogenesis #RegenerativeMedicine #TissueEngineering #Organoids #DrugDiscovery #StemCells #LifeScience #CELLvo #StemBioSys

Introducing CELLvo™ Human Chondrocytes AND CELLvo™ ChondroMatrix Young, healthy cells at early passage, or older, uncultured osteoarthritic cells – your choice. We offer the means for a deeper understanding of authentic chondrocyte behavior. Broaden your knowledge by comparing healthy and diseased chondrocytes, or expand chondrocyte cultures while maintaining potency and natural phenotype with reduced dedifferentiation. When you grow CELLvo™ Human Chondrocyte cells on CELLvo™ ChondroMatrix, you have the ability to truly empower your research. https://lnkd.in/dMmnJeQ

Immature hiPSC-CMs often fail to model mitochondrial cardiotoxicity, so improving metabolic maturity could make drug safety screening more predictive. Human perinatal stem cell-derived extracellular matrix (ECM), commercially known as CELLvo™ Matrix Plus, drove rapid structural and functional maturation of human iPSC-derived cardiomyocytes (hiPSC-CMs) after thawing from cryopreservation—within 7 days, rather than the weeks to months typically required for maturation. hiPSC-CMs grown on CELLvo™Matrix Plus developed morphology much closer to adult cardiomyocytes. Structural maturation included: *Rod-shaped morphology (instead of rounded/fetal-like cells) *Better sarcomere organization *Alignment of cytoskeletal structures from cell-to-cell *More mature contractile architecture Why does this matter? Morphology and sarcomere organization are hallmarks of cardiac maturity and influence function, contractility, and predictive value in drug testing. To learn more about CELLvo™ Matrix Plus, visit our website at www.stembiosys.com To purchase CELLvo™ Matrix is a variety of flasks and multiwell formats, visit https://lnkd.in/giHA8v3M

BOGO Deal on All CELLvo™ MSCs - Final Days to Save   If you're anything like us, you've noticed that prices have gone up on almost everything. Now's the time to save on all CELLvo™ MSCs! Next day shipping available.    CELLvo™ MSCs are the only cells isolated and expanded using StemBioSys’ CELLvo™ Xeno-Free Matrix technology. By isolating cells on a cell-derived extracellular matrix, we are able to preserve more natural phenotypes. With multiple donors to choose from, you can plan your current and future studies. Choose from Bone Marrow or Adipose Derived, Amniotic Membrane or Wharton's Jelly cells.  MSC features:  -Human cells (male and female options) -1 million cells at Passage 2 -Isolated and expanded in xeno-free conditions To purchase online, visit our website and add two vials of any MSC to your cart. Once you checkout, your BOGO Deal will automatically be applied. Limited to 3 free vials per customer. All CELLvo™ products are for Research Use Only and are not indicated for human use.  Visit our website at https://lnkd.in/gX33e2Gd Request a Quote at info@stembiosys.com

Join military and civilian leaders, researchers, and innovators to explore breakthrough technologies, share cutting-edge research, and forge partnerships that will transform healthcare for our service members and beyond. Come see why StemBioSys® CELLvo™ Cells and Cell-derived matrices are the next evolution in cell culture. We look forward to meeting you in the exhibit hall at our table. Visit our website www.stembiosys.com or email us at info@stembiosys.com.

BOGO Deal on All CELLvo™ MSCs - Final Days to Save   If you're anything like us, you've noticed that prices have gone up on almost everything. Now's the time to save on all CELLvo™ MSCs! Next day shipping available.    CELLvo™ MSCs are the only cells isolated and expanded using StemBioSys’ CELLvo™ Xeno-Free Matrix technology. By isolating cells on a cell-derived extracellular matrix, we are able to preserve more natural phenotypes. With multiple donors to choose from, you can plan your current and future studies. Choose from Bone Marrow or Adipose Derived, Amniotic Membrane or Wharton's Jelly cells.  MSC features:  -Human cells (male and female options) -1 million cells at Passage 2 -Isolated and expanded in xeno-free conditions To purchase online, visit our website and add two vials of any MSC to your cart. Once you checkout, your BOGO Deal will automatically be applied. Limited to 3 free vials per customer. All CELLvo™ products are for Research Use Only and are not indicated for human use.  Visit our website at https://lnkd.in/gX33e2Gd Request a Quote at info@stembiosys.com

In the world of primary cell culture, one of the biggest challenges researchers face is maintaining physiological relevance outside the body. Traditional plastic surfaces or even simple coatings often fall short—especially when working with sensitive, primary adherent cells that rapidly lose phenotype, function, and responsiveness. This is where cell-derived matrices are changing the game. Cell-derived matrices more closely replicate the native extracellular environment, providing not just structural support, but also the biochemical and mechanical cues that cells rely on in vivo. The result? Improved cell attachment, enhanced viability, and more consistent functional behavior over time. One solution that continues to stand out is CELLvo™ Matrix Plus for the culture of cardiomyocytes. By leveraging a complex, naturally deposited extracellular matrix, CELLvo™ Matrix Plus enables: 🔬 More physiologically relevant cell morphology 📈 Maturation in as little as 7 Days 🧬 Better retention of native phenotype and gene expression ⚙️ Improved assay reproducibility and predictive power For researchers working in drug discovery, disease modeling, or regenerative medicine, these advantages can translate into more reliable data and ultimately better decisions earlier in the pipeline. As the field continues to move toward more predictive in vitro models, incorporating biologically relevant substrates like cell-derived matrices isn’t just an upgrade—it’s becoming essential. Curious how others are integrating ECM-based systems into their workflows? Let’s connect and share insights. Take a look at all CELLvo™ Matrices to find the one that works best for your cells. https://lnkd.in/gA36ph4b Questions ... contact info@stembiosys.com to chat with one of our matrix experts. #CellCulture #PrimaryCells #ExtracellularMatrix #DrugDiscovery #LifeSciences #RegenerativeMedicine #CELLvo